A new study published in European Urology concluded that a common prostate cancer therapy known as ADT should not be used in men whose cancer has not spread beyond the prostate. Researchers found that the therapy exposed them to more adverse side effects and was associated with increased risk of death and deprived the men of the opportunity for a cure by other methods. ADT or androgen deprivation therapy involves injecting or implanting...